论文部分内容阅读
自1947年发现舒拉明和海群生以来,抗丝虫病化疗药物研究的进展甚为缓慢。由于上述二药具毒副反应,尤其对盘尾丝虫疗效更不理想,近年来对危害人类最烈、且导致患者失明的盘尾丝虫病的化疗药物的研究已引起重视。“世界卫生组织”等机构也筹拨专款建立“盘尾丝虫病化学治疗项目”(OCT)进行研究。现将目前药物研究的进展概述如下。一、现有药物使用方法的改进 1.给药方案舒拉明为目前治疗致盲盘尾丝虫病的药物,临床试验肯定总剂量60mg/kg为最低
Since the discovery of suramin and sea fauna in 1947, the progress of studies on anti-filariasis chemotherapeutic drugs has been slow. Due to the above two drugs have side effects, especially less effective on Onchocerciasis, in recent years, research on chemotherapeutic drugs that are most harmful to humans and lead to blindness in patients has been given attention. The World Health Organization and other agencies also made special donations to set up an onchocerciasis chemotherapy project (OCT) for research. The current progress in drug research is summarized below. First, the improvement of existing drug use 1. Sulalamin drug treatment for the treatment of blind onchocerciasis drugs, clinical trials certainly the total dose of 60mg / kg is the lowest